Despite EGFR inhibitors having dramatically improved the survival outcomes and quality of life of EGFR-positive NSCLC patients, drug-resistance mechanisms invariably emerge after treatment, leading to tumor progression within 2 years [4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.